Eli Lilly (LLY)
(Delayed Data from NYSE)
$829.74 USD
-17.09 (-2.02%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $827.15 -2.59 (-0.31%) 7:34 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LLY 829.74 -17.09(-2.02%)
Will LLY be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LLY
Company News for Oct 31, 2024
Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
ADP Higher Than Expected
Goldilocks ADP Jobs Numbers, Q3 GDP and Earnings
Other News for LLY
Interesting LLY Put And Call Options For December 13th
Pfizer: Overstated Pessimism Makes Little Sense
Biogen slips as Morgan Stanley downgrades on Leqembi launch
Eli Lilly Shares Hit Yearly Low After Disappointing Q3 Earnings
Jefferies Remains a Buy on Eli Lilly & Co (LLY)